ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Jun 15, 2022 → Apr 30, 2027
NCT ID
NCT05405595About ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib) is a phase 1/2 stage product being developed by Merck for Advanced/Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05405595. Target conditions include Advanced/Metastatic Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05405595 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors